Allstocks.com's Bulletin Board: Post A Reply

Post A Reply
my profile login | register | search | faq | forum home

»	Allstocks.com's Bulletin Board » Micro Penny Stocks, Penny Stocks $0.10 & Under » PKTX...The Beat Goes On..! » Post A Reply

Post A Reply
Login Name:
Password:
Message Icon:
Message: HTML is not enabled. UBB Code™ is enabled.	[QUOTE]Originally posted by jackbequick: [QB] ProtoKinetix Completes First Year of Trials on Retinal Replacement Therapy Using AAGP™ St. Marys, West Virginia, May 24, 2017 ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) today announces that it has completed the first year of retinal replacement therapy trials on animals and the results are encouraging enough to proceed to a second phase of testing. There are several diseases that, over time, destroy retinal cells ultimately causing blindness. These diseases include Age Related Macular Degeneration (AMD), Retinitis Pigmentosa (RP), and Stargardt disease. To date there are no effective treatments. Stem cell therapy has been viewed as a very exciting potential avenue that may allow the replacement or repair of these damaged retinal cells. About Age Related Macular Degeneration About Retinitis Pigmentosa About Stargardt Disease The study conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia compared the results of transplanted retinal precursor cells with and without the addition of AAGP™. The cells treated with AAGP™ showed an improvement on cell survivability and viability compared to the untreated cells. Ongoing testing is now being conducted to determine if these transplanted cells are fully functioning. Dr. Gregory-Evans Bio The results of these tests have serious implications for the treatment of other diseases that may benefit from stem cell transplant such as spinal cord injury and the repair of brain damage from stroke. The Company will be exploring the potential of these protocols and procedures using AAGP™ on brain damage caused by ischemic stroke in the coming months. [/QB][/QUOTE]

Instant Graemlins	Instant UBB Code™
	What is UBB Code™?

Options

Disable Graemlins in this post.

T O P I C R E V I E W

jackbequick

posted

ProtoKinetix Completes First Year of Trials on Retinal Replacement Therapy Using AAGP™
St. Marys, West Virginia, May 24, 2017
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) today announces that it has completed the first year of retinal replacement therapy trials on animals and the results are encouraging enough to proceed to a second phase of testing.

There are several diseases that, over time, destroy retinal cells ultimately causing blindness. These diseases include Age Related Macular Degeneration (AMD), Retinitis Pigmentosa (RP), and Stargardt disease. To date there are no effective treatments. Stem cell therapy has been viewed as a very exciting potential avenue that may allow the replacement or repair of these damaged retinal cells.

About Age Related Macular Degeneration

About Retinitis Pigmentosa

About Stargardt Disease

The study conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia compared the results of transplanted retinal precursor cells with and without the addition of AAGP™. The cells treated with AAGP™ showed an improvement on cell survivability and viability compared to the untreated cells. Ongoing testing is now being conducted to determine if these transplanted cells are fully functioning.

Dr. Gregory-Evans Bio

The results of these tests have serious implications for the treatment of other diseases that may benefit from stem cell transplant such as spinal cord injury and the repair of brain damage from stroke. The Company will be exploring the potential of these protocols and procedures using AAGP™ on brain damage caused by ischemic stroke in the coming months.